Streetbeat News

Analyst Ratings

AXSM

Axsome Therapeutics (NASDAQ:AXSM) has received mostly bullish ratings from analysts in the last quarter, with 5 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target for the stock, according to 8 analysts, is $118.62, a decrease of 3.4% from the previous average of $122.80.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 7:00 pm

SCHW

Charles Schwab's (NYSE:SCHW) short percent of float has decreased by 8.59% since its last report, with 19.44 million shares sold short, representing 1.17% of all regular shares available for trading. This decrease in short interest could indicate a more bullish sentiment towards the stock. However, it does not necessarily mean that the stock price will rise in the near term. Compared to its peers, Charles Schwab has less short interest, with an average of 3.66% for its peer group.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 6:45 pm

PCG

PG&E's (NYSE:PCG) short percent of float has fallen 27.91% since its last report, with 25.63 million shares sold short, which is 1.24% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards PG&E. Compared to its peers, PG&E has less short interest as a percentage of float, with an average of 2.29%.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 6:45 pm

ROK

Rockwell Automation's (NYSE:ROK) short percent of float has fallen 11.08% since its last report, with 3.17 million shares sold short, which is 3.13% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards the stock. Compared to its peers, Rockwell Automation has less short interest.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 6:45 pm

BCLI

BPTS

GWH

MORF

RNAZ

SCYX

U.S. stocks traded mixed with the Nasdaq Composite trading higher and the Dow trading down. TransCode Therapeutics shares surged 218% after announcing pre-clinical gliblastoma results. ESS Tech shares rose 24% after Honeywell International entered into a strategic collaboration with ESS Tech. Biophytis shares gained 54% after announcing a partnership agreement for the production of Sarconeos for severe forms of Covid-19. SCYNEXIS shares dropped 34% after recalling BREXAFEMME and halting clinical studies. Brainstorm Cell Therapeutics shares were down 33% after the FDA said there is insufficient evidence to support the company's ALS therapy. Morphic Holding shares fell 37% after BTIG downgraded the stock from Buy to Neutral.

Portfolio Pulse from Lisa Levin

September 25, 2023 | 6:43 pm

ADBE

Adobe's (NYSE:ADBE) short percent of float has risen 5.68% since its last report, with 4.25 million shares sold short, which is 0.93% of all regular shares available for trading. Short interest can act as an indicator of market sentiment towards a stock. Adobe's peer group average for short interest as a percentage of float is 3.31%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 6:30 pm

NEM

Newmont's (NYSE:NEM) short percent of float has risen 4.49% since its last report, with 29.42 million shares sold short, which is 4.19% of all regular shares available for trading. This increase in short interest can signal that investors have become more bearish. Newmont's peer group average for short interest as a percentage of float is 2.89%, indicating the company has more short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 6:30 pm

NOC

Northrop Grumman's (NYSE:NOC) short percent of float has fallen 5.62% since its last report, with 1.27 million shares sold short, which is 0.84% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Northrop Grumman has less short interest.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 6:30 pm

MORF

Stifel analyst Alex Thompson maintains a 'Hold' rating on Morphic Holding (NASDAQ:MORF) and has lowered the price target from $61 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 6:26 pm

XOM

Morgan Stanley analyst Devin McDermott has reiterated an Overweight rating on Exxon Mobil Corp (XOM) and raised the price target from $124 to $131. The analyst highlighted that about 60% of the earnings improvement has already been delivered, putting XOM slightly ahead of plan. The company's strategic shift towards biofuels and integrated portfolio is paying off, with 12 biofuels opportunities under development offering above 20% returns. XOM's portfolio is now 85% integrated with its chemical facilities, and the company is increasing its sales of performance products.

Portfolio Pulse from Shivani Kumaresan

September 25, 2023 | 6:22 pm